Naturally occurring compounds as pancreatic cancer therapeutics

Ines Lohse, Erin Wildermuth, Shaun P Brothers

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.

Original languageEnglish (US)
Pages (from-to)35448-35457
Number of pages10
JournalOncotarget
Volume9
Issue number83
StatePublished - Oct 1 2018

Fingerprint

Pancreatic Neoplasms
Curcumin
Cannabinoids
Neoplasms
Drug Therapy
Therapeutics
Research
resveratrol

Keywords

  • Curcumin
  • Natural compounds
  • Pancreatic cancer
  • Resveratrol
  • Taxane

ASJC Scopus subject areas

  • Oncology

Cite this

Naturally occurring compounds as pancreatic cancer therapeutics. / Lohse, Ines; Wildermuth, Erin; Brothers, Shaun P.

In: Oncotarget, Vol. 9, No. 83, 01.10.2018, p. 35448-35457.

Research output: Contribution to journalReview article

Lohse, I, Wildermuth, E & Brothers, SP 2018, 'Naturally occurring compounds as pancreatic cancer therapeutics', Oncotarget, vol. 9, no. 83, pp. 35448-35457.
Lohse, Ines ; Wildermuth, Erin ; Brothers, Shaun P. / Naturally occurring compounds as pancreatic cancer therapeutics. In: Oncotarget. 2018 ; Vol. 9, No. 83. pp. 35448-35457.
@article{650ce177e2454d1c908c0a30c0ff0d74,
title = "Naturally occurring compounds as pancreatic cancer therapeutics",
abstract = "Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.",
keywords = "Curcumin, Natural compounds, Pancreatic cancer, Resveratrol, Taxane",
author = "Ines Lohse and Erin Wildermuth and Brothers, {Shaun P}",
year = "2018",
month = "10",
day = "1",
language = "English (US)",
volume = "9",
pages = "35448--35457",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "83",

}

TY - JOUR

T1 - Naturally occurring compounds as pancreatic cancer therapeutics

AU - Lohse, Ines

AU - Wildermuth, Erin

AU - Brothers, Shaun P

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.

AB - Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.

KW - Curcumin

KW - Natural compounds

KW - Pancreatic cancer

KW - Resveratrol

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=85055669114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055669114&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85055669114

VL - 9

SP - 35448

EP - 35457

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 83

ER -